WESTLAKE VILLAGE, Calif., March 15 /PRNewswire-FirstCall/ -- BioElectronics Corporation, , announced today it has commenced a series of double-blind clinical trials to be conducted in conjunction with leading schools of podiatry and selected clinics to document the effects of ActiPatch on treating plantar fasciitis [heel pain]. The studies are starting this month with early results expected within 90 days. The Principal Investigator for the study is Dr. William Van der Reis, a Board Certified Orthopedic Surgeon and sports medicine specialist. The study protocol was approved by the Investigational Review Board, Coast IRB, of San Clemente, CA.
The Company anticipates submission of the trial results to the FDA to obtain additional regulatory clearances. “This series of clinical trials are essential to establish broader regulatory and market approval for our expanded line of innovative drug-free, anti-inflammatory products, said Thomas O’Connor, Chief Operating Officer. “We are grateful to our clinical partners and to our Medical Advisory Board for all the efforts they have put forth in getting these important research projects moving forward.”
ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
BioElectronics Corporation
CONTACT: Andrew J. Whelan, President & CEO, or Thomas O’Connor, EVPOperations & COO, both of BioElectronics Corporation, +1-301-644-3906, Fax:+1-301-644-3939, info@bioelectronicscorp.com
Web site: http://www.bioelectronicscorp.com/
